2179 — Jiangsu Recbio Technology Co Income Statement
0.000.00%
- HK$4.30bn
- HK$4.02bn
Annual income statement for Jiangsu Recbio Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 62.1 | 142 | 601 | 732 | 559 |
Operating Profit | -62.1 | -142 | -601 | -732 | -559 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -138 | -179 | -658 | -736 | -572 |
Provision for Income Taxes | |||||
Net Income After Taxes | -138 | -179 | -658 | -736 | -572 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -138 | -179 | -658 | -723 | -572 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -138 | -179 | -658 | -723 | -572 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.289 | -0.374 | -1.33 | -1.5 | -1.18 |